Sun Pharma Advanced Research Company Ltd. And Sun Pharmaceutical Industries Ltd. and includes its subsidiaries or associate companies) announced a licensing arrangement for SPARC’s ELEPSIA XRTM (Levetiracetam Extended Release tablets).
As part of its business strategy to build a meaningful & differentiating presence in Global Oncology Therapy market, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today announced the roll-out of Gemcitabine InfuSMART in Europe. InfuSMART is a technology in which oncology products are developed in a Ready-To-Administer (RTA) bag.
Sun Pharma acquired established prescription brands from Novartis AG and Novartis Pharma AG (together ‘Novartis’) in Japan. In a $293 million cash deal India's Sun Pharmaceutical Industries Ltd. has agreed to buy 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan, the Indian company said.
Sun Pharma and AstraZeneca Pharma India Limited announced a partnership for the distribution of dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is AstraZeneca India’s leading diabetes medicine.
Sun Pharma launched therapeutic equivalent to Gleevec® in the US market. Sun Pharma’s subsidiary received final approval for Imatinib Mesylate from FDA in December 2015.
Drug major Sun Pharmacuetical Industries Ltd on Saturday said it has received a warning letter from USFDA relating to its facility in Halol in Gujarat.